{{Rsnum
|rsid=4522336
|Chromosome=14
|position=48556315
|Orientation=plus
|GMAF=0.1042
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 67.0 | 31.2 | 1.8
| HCB | 91.2 | 8.8 | 0.0
| JPT | 95.5 | 4.5 | 0.0
| YRI | 98.0 | 2.0 | 0.0
| ASW | 80.7 | 19.3 | 0.0
| CHB | 91.2 | 8.8 | 0.0
| CHD | 97.2 | 2.8 | 0.0
| GIH | 76.0 | 23.0 | 1.0
| LWK | 97.2 | 2.8 | 0.0
| MEX | 75.9 | 24.1 | 0.0
| MKK | 96.1 | 3.9 | 0.0
| TSI | 64.7 | 33.3 | 2.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs4522336
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: C, MAF= 0.16, combined P value= 3.47E-04. It is also associated with etoposide clearance.
|Drugs=etoposide
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470234
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs4522336
|overall_frequency_n=15
|overall_frequency_d=128
|overall_frequency=0.117188
|n_genomes=12
|n_genomes_annotated=0
|n_haplomes=12
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}
{{on chip | 23andMe v3}}
{{on chip | Affy GenomeWide 6}}